ライフサイエンスコーパス: unresectable

1 33-83 years); all lesions were confirmed as unresectable.

2 roscopy and the probability that disease was unresectable.

3 Of these, 5 were unresectable.

4 %) were considered unresectable (286 locally unresectable, 244 with distant metastasis).

5 rgically explored, 530 (49%) were considered unresectable (286 locally unresectable, 244 with distant

6 ible in achieving local control of otherwise unresectable abdominal tumors.

7 Eligibility included stage II or III unresectable adenocarcinoma of the pancreas, performance

8 Patients with advanced, unresectable, American Joint Committee on Cancer stage I

9 arcoma of childhood, yet the outcome for the unresectable and metastatic disease is dismal and unchan

10 nts and Methods Patients < 18 years old with unresectable and/or progressive therapy-naive PLGG were

11 ncer stage III LA/BR PDAC who were initially unresectable, as determined by staging computed tomograp

12 V CRC have liver disease which is considered unresectable at presentation.

13 No patient developed unresectable BD-IPMN carcinoma during follow-up.

14 is best suitable for locally invasive tumors unresectable because of location and vascular involvemen

15 ac and superior mesenteric artery are deemed unresectable by conventional surgical methods.

16 iopsy-confirmed HCC or ICC, determined to be unresectable by multidisciplinary review, with a Child-T

17 ive group setting, patients with LEC who had unresectable cancer, were unwilling to undergo surgery,

18 compared with those who had locally advanced unresectable cancers (14 vs 11 months; P < 0.001).

19 evaluated among patients with metastatic or unresectable carcinoid tumors.

20 Unresectable chemorefractory colon cancer liver metastas

21 Thirty patients with unresectable chemorefractory CRLM were treated with resi

22 Fifteen patients with unresectable, chemorefractory liver metastases of any or

23 emerged as a valuable therapeutic option in unresectable, chemotherapy-refractory hepatic metastases

24 current endoscopic palliative modalities for unresectable cholangiocarcinoma are reviewed, focusing o

25 Twenty-nine patients with unresectable cholangiocarcinoma, including 11 men (mean

26 ents with previously untreated metastatic or unresectable clear-cell renal-cell carcinoma received or

27 forty-six patients (65% males) with locally unresectable colon (40) and rectal (106) cancer were tre

28 or never should be resected in patients with unresectable colorectal cancer metastases must be questi

29 Forty-nine patients with unresectable colorectal liver metastases (CRLM) were inc

30 d with a separate cohort of 82 patients with unresectable colorectal liver metastases treated with be

31 Evaluate conversion rate of patients with unresectable colorectal-liver metastasis to complete res

32 f modern chemotherapy on rendering initially unresectable CRC liver metastases resectable, while at t

33 In patients with extensive unresectable CRLM, the majority of whom were previously

34 erapies will benefit patients with advanced, unresectable CRTC1-MAML2-positive MEC.

35 neoadjuvant chemotherapy, whereas those with unresectable disease (> or = cT4b, N+, or M+) received t

36 h was particularly notable for patients with unresectable disease (15 vs. 6 months, P = 0.003).

37 37; 95% CI: 1.15-1.63) but not in those with unresectable disease (HR: 1.07; 95% CI: 0.89-1.29).

38 l lymph nodes (n = 47), and locally advanced unresectable disease (n = 18), that is, 6-DL and 69-UDL.

39 apeutic laparotomy in 55.9% of patients with unresectable disease and 23.2% of overall GBC patients.

40 However, the accuracy in detecting unresectable disease and a DL in locally advanced tumors

41 e tumors; however, the accuracy in detecting unresectable disease and a DL were similar.

42 The accuracy of SL for detecting unresectable disease and DL was 55.9% (95/170) and 94.1%

43 Most patients present with unresectable disease and features of biliary obstruction

44 nhibitors and tyrosine kinase inhibitors for unresectable disease are promising in expanding treatmen

45 91 patients evaluated, 22 patients (24%) had unresectable disease at presentation.

46 Exclusion criteria included metastatic or unresectable disease at surgery, positive surgical margi

47 o underwent laparotomy, an additional 75 had unresectable disease due to surface liver metastasis (n

48 For most sarcomas, locally advanced or unresectable disease is still treated with cytotoxic che

49 For patients with unresectable disease or multiple recurrences, systemic t

50 te responders," and the remainder either had unresectable disease or were unfit for surgery.

51 Other metastatic and locally advanced unresectable disease qualified as undetectable lesions (

52 Most patients (n = 115, 73.7%) with unresectable disease were treated with chemotherapy, eit

53 In unresectable disease, consideration should be given to s

54 randomised, phase 3 trial, had metastatic or unresectable disease, Eastern Cooperative Oncology Group

55 In unresectable disease, the question is how best to get th

56 In FNAs obtained from 17 patients with unresectable disease, we identified at least 1 driver ge

57 systemic treatment exists for patients with unresectable disease.

58 41 patients but abandoned in nine because of unresectable disease.

59 been limited effective treatment options for unresectable disease.

60 y treatment and newer systemic therapies for unresectable disease.

61 ole of systemic chemotherapy in treatment of unresectable disease.

62 advances in systemic therapy for those with unresectable disease.

63 ly, 80-85% of patients present with advanced unresectable disease.

64 days +/- 39 days) from time of diagnosis of unresectable disease.

65 because of improved nonoperative therapy for unresectable disease.

66 cancer that typically presents as advanced, unresectable disease.

67 patients with liver malignancies considered unresectable due to an insufficient FLR who underwent AL

68 For unresectable early-stage HCCA, excellent long-term tumor

69 and pelvic sidewall) are considered locally "unresectable" for cure and treated with palliative thera

70 el treatment strategies for deadly recurrent unresectable forms of this soft tumor subtype, but also

71 f regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least

72 Patients with metastatic or surgically unresectable GIST were eligible for this phase III open-

73 with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous ima

74 ted, histologically confirmed, metastatic or unresectable GISTs.

75 hepatocellular carcinoma (HCC) are <50%, and unresectable HCC carries a dismal prognosis owing to its

76 cant therapeutic benefit of TACE plus RT for unresectable HCC compared with TACE alone.

77 n of sorafenib and DEB-TACE in patients with unresectable HCC is well tolerated and safe, with most t

78 (96 men, 20 women; mean age, 63 years) with unresectable HCC who underwent at least two chemoemboliz

79 It included 79 patients with unresectable HCC who were treated with TACE.

80 Inclusion criteria included unresectable HCC, a treatment naive status, an Eastern C

81 After IAT for unresectable HCC, patients can be stratified into signif

82 study was undertaken involving patients with unresectable HCC.

83 ell tolerated, and may benefit patients with unresectable HCC.

84 urrently considered a first-line therapy for unresectable HCC.

85 ld be recommended for suitable patients with unresectable HCC.

86 n shown to improve survival in patients with unresectable HCC; it has also been successfully used as

87 ecome a real alternative in the treatment of unresectable hepatic cancers.

88 Unresectable hepatic colorectal cancer (CRC) metastases

89 [SIRT]) is a valuable therapeutic option for unresectable hepatic metastases arising from primary col

90 Twelve patients with initially unresectable hepatoblastoma were enrolled in the study.

91 For the management of selected children with unresectable hepatoblastoma, an almost opposite strategy

92 vide a novel local therapy for patients with unresectable hepatoblastoma.

93 survival and tumor response in patients with unresectable hepatocellular carcinoma (HCC) treated with

94 from a phase 2 study in which patients with unresectable hepatocellular carcinoma (HCC) with and wit

95 mbolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC).

96 on therapy (SIRT) is a valuable treatment in unresectable hepatocellular carcinoma (HCC).

97 to compare survival of patients treated for unresectable hepatocellular carcinoma (uHCC) with (90)Y

98 standard of care for patients with advanced unresectable hepatocellular carcinoma, but the relation

99 nsplantation was first used in patients with unresectable hilar CCAs, these methods have yet to reach

100 Sixty-five patients with unresectable hilar cholangiocarcinoma (CCA) have undergo

101 OLT in appropriately selected patients with unresectable ICCA demonstrated promising disease recurre

102 al can be achieved in selected patients with unresectable ICCA using a combination of OLT and neoadju

103 However, in the case of unresectable ICCA, data on outcomes after OLT are limite

104 nts being considered for transplantation for unresectable ICCA.

105 f liver transplant criteria for treatment of unresectable ICCA.

106 Malignant tumors are considered "unresectable" if they are adhere to vital structures or

107 ly with thoracic radiation for patients with unresectable IIIA and IIIB non-small-cell lung cancer (N

108 rolled and analyzed; inclusion criteria were unresectable IIIA/IIIB histologically confirmed NSCLC, K

109 atients with relapsed ALCL and metastatic or unresectable IMT highlight the importance of the ALK pat

110 neoadjuvant) versus patients presenting with unresectable lesions, for which chemotherapy is used to

111 one of the principal tools in management of unresectable liver malignancies, including colorectal li

112 ATIENTS AND METHODS Forty-nine patients with unresectable liver metastases (53% previously treated wi

113 0)Y-yttrium microsphere radioembolization of unresectable liver metastases from breast cancer.

114 conversion to resectability in patients with unresectable liver metastases from colorectal cancer tre

115 e regimen for the treatment of patients with unresectable liver metastases from colorectal cancer, de

116 emotherapy can be recommended for downsizing unresectable liver metastases, but not for resectable le

117 For unresectable liver metastases, combination regimens resu

118 n excellent response rates for patients with unresectable liver metastasis from solid tumors.

119 on (TAE) has been extensively used to manage unresectable liver tumors.

120 who undergo yttrium 90 radioembolization for unresectable liver-dominant metastatic colorectal cancer

121 in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma.

122 LT is an effective treatment of unresectable LM from NET.

123 Isolated unresectable LMs are often the main determinant of overa

124 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis.

125 igned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mu

126 We recruited adults (aged >/=18 years) with unresectable locally advanced or metastatic gastric or g

127 We recruited patients (>/=18 years old) with unresectable locally advanced or metastatic gastric or o

128 METHODS Patients with unresectable locally advanced or metastatic hereditary M

129 Patients with unresectable locally advanced or metastatic pancreatic a

130 logical evidence of metastatic or surgically unresectable locally advanced sarcoma, had received up t

131 years or older with metastatic or surgically unresectable locally advanced urothelial carcinoma, meas

132 A 52-year-old man has unresectable locally recurrent melanoma of the left foot

133 en aged 18 years or older with HER2-positive unresectable, locally advanced or metastatic breast canc

134 number of previous chemotherapy regimens for unresectable, locally advanced, or metastatic disease (0

135 d for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric ca

136 han drug' for the treatment of patients with unresectable, locally advanced, or metastatic medullary

137 This trend is exaggerated in unresectable, locally invasive or metastatic tumors, in

138 rial evaluated ramucirumab with docetaxel in unresectable, locally recurrent, or metastatic breast ca

139 d/or radiation) for incompletely resected or unresectable low-grade glioma (LGG).

140 ey met the following criteria: metastatic or unresectable lung cancer harbouring a RET rearrangement,

141 herapy with RF ablation after SPACE to treat unresectable lung tumors is technically feasible, safe,

142 Thirty-nine patients with surgically unresectable malignant liver tumors, including 34 patien

143 een resectable mesenteric lymph nodes versus unresectable masses in the root of the mesentery.

144 these patients were treated who had advanced unresectable melanoma arising from acral, mucosal, and c

145 (RAF) kinase inhibitor vemurafenib to treat unresectable melanoma.

146 and Drug Administration for the treatment of unresectable melanoma.

147 In the subpopulation of patients with an unresectable meningioma and refractory to radiotherapy,

148 Patients with progressive unresectable meningioma were treated with (90)Y-DOTATOC

149 are promising tools for treating progressive unresectable meningioma, especially in cases of high tra

150 tolerated but had no impact on patients with unresectable meningioma.

151 the role of mifepristone in the treatment of unresectable meningioma.

152 ere 95% for resectable tumors versus 78% for unresectable mesenteric tumors (P = .02).

153 Outcomes for OS presenting with unresectable metastases or recurrent disease, or in thos

154 plus or minus biologics, to render initially unresectable metastases resectable has increased the per

155 Unresectable metastatic bone sarcoma and soft-tissue sar

156 Unresectable metastatic colorectal cancer (CRC) can be r

157 view the landscape of systemic therapies for unresectable metastatic colorectal cancer during the cur

158 overall survival of patients diagnosed with unresectable metastatic colorectal cancer has increased

159 FOLFOXIRI-Bev for the treatment of initially unresectable metastatic colorectal cancer in humans were

160 For patients with surgically unresectable metastatic colorectal cancer, FOLFOXIRI-Bev

161 c NET and 41 with nonpancreatic GEP NET) had unresectable metastatic disease graded as G1 or G2 (G1/G

162 tact primary tumor (IPT) and synchronous yet unresectable metastatic disease.

163 ession in up to 50% or more of patients with unresectable metastatic melanoma.

164 0 years and older with previously untreated, unresectable, metastatic colorectal cancer, who were not

165 ed primarily due to medical inoperability or unresectable/metastatic disease after chemoradiotherapy.

166 trial in patients with previously untreated, unresectable MM.

167 In unresectable MRD, PNB nanosurgery improved survival twof

168 = 3) or exenteration (n = 11) or were judged unresectable (n = 13).

169 27 men, 17 women) with resectable (n = 12), unresectable (n = 29), and metastatic (n = 3) pancreatic

170 ficult to select treatment for patients with unresectable NETs because some patients can survive deca

171 improves survival in patients with stage III unresectable non-small-cell lung cancer when given as ma

172 onsidered for the treatment of patients with unresectable nonmetastatic disease and for patients with

173 and Methods Chemotherapy-naive patients with unresectable, nonsarcomatoid MPM (Eastern Cooperative On

174 ed further in patients with locally advanced unresectable nonsquamous NSCLC.

175 Concurrent chemotherapy and PBT to treat unresectable NSCLC afford promising clinical outcomes an

176 ive radiotherapy for patients with stage III unresectable NSCLC.

177 dependent prognostic factor in patients with unresectable oesophageal squamous cell carcinoma.

178 arly stage hilar cholangiocarcinoma which is unresectable or arising in the setting of primary sclero

179 tis in patients treated with vemurafenib for unresectable or metastatic cutaneous melanoma.

180 be an effective treatment for patients with unresectable or metastatic DFSP, associated with respons

181 the current preferred agent for treatment of unresectable or metastatic DFSP.

182 Patients with either unresectable or metastatic disease were studied.

183 Most patients with BTC will present with unresectable or metastatic disease.

184 rlotinib remains the standard of therapy for unresectable or metastatic disease.

185 mean age, 60 years; range, 28-79 years) with unresectable or metastatic HCC were studied.

186 e the overall survival (OS) of patients with unresectable or metastatic hepatocellular carcinoma (HCC

187 and Drug Administration for the treatment of unresectable or metastatic melanoma in patients with Bra

188 D-1 mAbs for the treatment of BRAF-unmutated unresectable or metastatic melanoma is a landmark for th

189 untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated wit

190 ligible patients were 18 years or older, had unresectable or metastatic melanoma, and progressed afte

191 I studies and now approved for patients with unresectable or metastatic melanoma.

192 For 12 patients with unresectable or metastatic SCUC, the median OS was 13.3

193 n plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 cli

194 ars or older with a diagnosis of an advanced unresectable or metastatic soft-tissue sarcoma, of inter

195 neligible patients with locally advanced and unresectable or metastatic urothelial cancer.

196 they had pathologically confirmed, advanced (unresectable or metastatic), non-functional, well-differ

197 ult patients (aged >18 years) with advanced (unresectable or metastatic), well differentiated carcino

198 arcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disea

199 nts were eligible if their tumour was either unresectable or of low surgical curability on the basis

200 stant metastases and tumors considered to be unresectable or were candidates for organ preservation)

201 patients with previously treated stage III (unresectable) or stage IV melanoma were randomly assigne

202 trial we enrolled patients with metastatic, unresectable, or locally advanced NSCLC from 121 sites i

203 cetaxel for patients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer.

204 We included patients with locally advanced, unresectable, or metastatic high-grade soft-tissue sarco

205 with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma were scr

206 xorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so

207 All 49 patients were deemed initially unresectable owing to vascular involvement.

208 compared with patients with locally advanced unresectable pancreatic adenocarcinoma.

209 For patients with locally advanced and unresectable pancreatic cancer (PDAC), neodadjuvant trea

210 t in survival and resectability of localized unresectable pancreatic cancer may be attained without r

211 survival of patients with locally advanced, unresectable pancreatic cancer treated with the combinat

212 years; 23 males, 27 females) with localized unresectable pancreatic cancer were eligible for this tr

213 on therapy to GEM in patients with localized unresectable pancreatic cancer, with acceptable toxicity

214 ed with GEM alone in patients with localized unresectable pancreatic cancer.

215 emoradiotherapy in borderline resectable and unresectable pancreatic cancer.

216 ontrolled trials involving locally advanced, unresectable pancreatic cancer.

217 valuable option for patients with initially unresectable pancreatic NETs.

218 Patients with inoperable or unresectable pancreatic neuroendocrine tumors (NETs) hav

219 All patients had a borderline or unresectable pancreatic tumor (group 1) or oligometastat

220 line-resectable patients, and one (7%) of 14 unresectable patients underwent resection after therapy.

221 borderline-resectable patients, and 47% for unresectable patients.

222 on therapy in patients with locally advanced unresectable PDA have reported mixed results, with effec

223 We reviewed all patients with unresectable perihilar CCA treated with neoadjuvant chem

224 chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma caused the Uni

225 n age, 64.0 years; 10 women and 29 men) with unresectable pleural mesothelioma were treated with repe

226 esponse in the treatment of recurrent and/or unresectable pleural mesothelioma.

227 centres across 19 countries in patients with unresectable pleural or peritoneal malignant mesotheliom

228 a better outcome than patients with multiple unresectable PM (5-year OS, 88%, 92%, and 48%, respectiv

229 Aggressive multimodality therapy for locally unresectable primary colorectal cancer results in excell

230 elapse and survival in patients with locally unresectable primary colorectal cancer.

231 well tolerated for patients with previously unresectable primary tumors and known metastatic disease

232 an 50% tumor resection at diagnosis, or with unresectable progressive disease after surgery alone.

233 vanced disease; 51 received chemotherapy for unresectable recurrent/metastatic disease.

234 Eligible patients had metastatic or unresectable renal carcinoma with a clear-cell component

235 ty as first-line treatment for metastatic or unresectable renal-cell carcinoma.

236 y can reduce the size of metastases that are unresectable rendering them resectable, and decrease pos

237 mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel thera

238 e consecutive adult patients with surgically unresectable single or multifocal measurable HCC and ade

239 cted database of patients undergoing IHP for unresectable solid tumor LM.

240 ntially offers more efficacious treatment of unresectable solid tumors without significant adverse si

241 tential to provide a theranostic solution to unresectable solid tumors.

242 microwave ablation (MWA) in the treatment of unresectable solitary hepatocellular carcinoma (HCC) up

243 Patients with treatment-naive, unresectable, solitary HCC </= 5 cm not amenable to RFA

244 nters with 42 patients who had inoperable or unresectable stage II to stage III NSCLC enrolled from N

245 Patients with stage IV or unresectable stage III melanoma were treated with TMZ 75

246 was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC

247 andomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC

248 Standard therapy for unresectable stage III non-small-cell lung cancer includ

249 ble-blind trial that recruited patients with unresectable stage III non-small-cell lung cancer who ha

250 e enrolled patients (aged >/= 18 years) with unresectable stage III non-small-cell lung cancer, a Zub

251 compared with placebo for all patients with unresectable stage III non-small-cell lung cancer.

252 of cetuximab with chemoradiotherapy (CRT) in unresectable stage III NSCLC.

253 rent chemotherapy and high-dose PBT to treat unresectable stage III NSCLC.

254 a In Solid Tumors version 1.1 (RECIST v1.1), unresectable stage III or IV melanoma (excluding ocular

255 Eligible patients (aged >/=18 years) with unresectable stage III or IV melanoma (treatment-naive o

256 18 years or older with previously untreated, unresectable stage III or IV melanoma and an Eastern Coo

257 atio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone

258 In this phase I study, 90 patients with unresectable stage III or IV melanoma who were ipilimuma

259 Eighty-eight patients with unresectable stage III or IV melanoma with at least one

260 il July 28, 2011, of patients (N = 245) with unresectable stage III or IV melanoma, at least 1 prior

261 Among patients with unresectable stage III or IV melanoma, treatment with ip

262 tal of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had

263 atients with untreated or previously treated unresectable stage III or IV melanoma, without previous

264 ials of nivolumab in 440 adult patients with unresectable stage III or stage IV melanoma, who had bee

265 isplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell

266 Patients with treatment-naive, unresectable stage IIIc or IV melanoma were randomly ass

267 cally confirmed BRAF(V600) mutation-positive unresectable stage IIIC or stage IV melanoma were random

268 ed 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF

269 RAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma.

270 ction (PTR) is recommended for patients with unresectable stage IV colorectal cancer (CRC) who presen

271 compared for 44 514 patients diagnosed with unresectable stage IV CRC from January 1, 1988, through

272 ribution of PTR to survival in patients with unresectable stage IV CRC over the past two decades in t

273 Of the 44 514 patients with unresectable stage IV CRC, 27 931 (62.7%) had undergone

274 c, and other-cause survival of patients with unresectable stage IV CRC.

275 lly confirmed, BRAF(V600) mutation-positive, unresectable, stage IIIC or IV melanoma.

276 PATIENTS AND METHODS Patients with unresectable stages I-III NSCLC were eligible.

277 Methods Patients with unresectable stages IIIB to IV melanoma, with no more th

278 lation included 185 Australian patients with unresectable stages IIIC and IV melanoma referred from C

279 Patients with metastatic or unresectable STS were randomly assigned to treatment wit

280 When administered to a patient with unresectable symptomatic suprasellar hemangioblastoma, o

281 those patients who are at risk for having an unresectable tumor and who should be referred to a liver

282 ntly better outcome compared with those with unresectable tumors (n = 43; 24%; P < 0.0001).

283 utic strategy for management of symptomatic, unresectable tumors by somatostatin analogue therapy.

284 In the cases of unresectable tumors embolization is used as a palliative

285 gnancy by imaging analysis for patients with unresectable tumors or who underwent neoadjuvant treatme

286 e therapies is either to allow patients with unresectable tumors to become surgical candidates, provi

287 is demonstrating utility in the treatment of unresectable tumors where thermal ablation techniques ar

288 survival benefit over locally advanced (LA) unresectable tumors.

289 herapy may improve survival particularly for unresectable tumors.

290 ction margins, regional nodal metastasis, or unresectable tumors.

291 en is believed to be useful in patients with unresectable tumors.

292 sectable tumors and was 25% in patients with unresectable tumors.

293 went pancreatectomy, and 4.0% (458/2736) had unresectable tumors.Patients were less likely to undergo

294 or resectable tumors; the utility of RFA for unresectable tumors; and RFA approaches (open, laparosco

295 atients with chemotherapy-naive, metastatic, unresectable uLMS were randomly assigned to gemcitabine-

296 h patients with symptomatic, multicentric or unresectable, unicentric CD received siltuximab at 1-, 2

297 ty in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progress

298 eated patients with metastatic or surgically unresectable urothelial carcinoma.

299 Surgically unresectable VHL-HBs or those in frail patients are chal

300 ty to a definitive answer (ie, resectable or unresectable) when the reports were structured than when